Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

NASDAQ: SHPH · IEX Real-Time Price · USD
1.08
-0.04 (-3.15%)
At close: Jun 2, 2023, 4:00 PM
1.09
+0.02 (1.40%)
After-hours: Jun 2, 2023, 7:59 PM EDT
-3.15%
Market Cap 14.84M
Revenue (ttm) n/a
Net Income (ttm) -3.37M
Shares Out 13.80M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 260,683
Open 1.14
Previous Close 1.11
Day's Range 1.07 - 1.15
52-Week Range 1.02 - 126.26
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 25, 2023

About SHPH

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland. [Read more]

Sector Healthcare
IPO Date Aug 31, 2022
Employees 7
Stock Exchange NASDAQ
Ticker Symbol SHPH
Full Company Profile

Financial Performance

Financial Statements

News

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

ROCKVILLE, Md. , May 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes fo...

1 week ago - PRNewsWire

Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

ROCKVILLE, Md. , May 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes fo...

2 weeks ago - PRNewsWire

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates

ROCKVILLE, Md. , March 22, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outco...

2 months ago - PRNewsWire
}

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update

ROCKVILLE, Md. , March 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes ...

2 months ago - PRNewsWire

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial

ROCKVILLE, Md. , March 9, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

3 months ago - PRNewsWire

Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities

ROCKVILLE, Md. , Feb. 23, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

3 months ago - PRNewsWire

Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31

ROCKVILLE, Md. , Jan. 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

4 months ago - PRNewsWire

Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023

ROCKVILLE, Md. , Jan. 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

4 months ago - PRNewsWire
}

Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants

ROCKVILLE, Md. , Jan. 12, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

5 months ago - PRNewsWire

Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications

ROCKVILLE, Md. , Jan. 10, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

5 months ago - PRNewsWire

Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update

ROCKVILLE, Md. , Nov. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

7 months ago - PRNewsWire

Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study

ROCKVILLE, Md. , Nov. 3, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcome...

7 months ago - PRNewsWire

Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors

ROCKVILLE, Md. , Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes...

7 months ago - PRNewsWire
}

Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine

Agreement to help advance lead clinical sensitizer drug candidate ROCKVILLE, Md. , Sept. 20, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development sta...

9 months ago - PRNewsWire

Shuttle Pharmaceuticals ($SHPH) Awarded New HDAC Inhibitor Patents for Cancer Treatment

Shuttle Pharmaceuticals ($SHPH), has announced that it has been awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, which is focused on reducing...

9 months ago - Green Stock News

Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment

Company awarded patents in the U.S. and Hong Kong ROCKVILLE, Md. , Sept. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pha...

9 months ago - PRNewsWire

Shuttle Pharmaceuticals Announces Closing of Initial Public Offering

ROCKVILLE, Md. , Sept. 6, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

9 months ago - PRNewsWire

Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH"

Shuttle Pharma's platform of sensitizers are designed to address the urgent clinical need to improve the outcomes of cancer patients treated with radiation therapy while reducing side effects ROCKVILL...

9 months ago - PRNewsWire

Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering

ROCKVILLE, Md. , Aug. 30, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

9 months ago - PRNewsWire

Shuttle Pharmaceuticals Holdings IPO Registration Document (S-1)

Shuttle Pharmaceuticals Holdings has filed to go public with an IPO on the NASDAQ

1 year ago - SEC